Mind Medicine (MindMed) Stock (NASDAQ:MNMD)
Previous Close
$7.01
52W Range
$3.46 - $12.22
50D Avg
$7.05
200D Avg
$7.68
Market Cap
$525.05M
Avg Vol (3M)
$1.17M
Beta
2.33
Div Yield
-
MNMD Company Profile
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
MNMD Performance
Peer Comparison
| Ticker | Company |
|---|---|
| RVPH | Reviva Pharmaceuticals Holdings, Inc. |
| CKPT | Checkpoint Therapeutics, Inc. |
| ATAI | Atai Life Sciences N.V. |
| VCNX | Vaccinex, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| GHRS | GH Research PLC |
| BPTH | Bio-Path Holdings, Inc. |
| KOD | Kodiak Sciences Inc. |
| ITOS | iTeos Therapeutics, Inc. |
| MBIO | Mustang Bio, Inc. |
| MOLN | Molecular Partners AG |
| OPT | Opthea Limited |